Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut Curie
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gradalis, Inc.
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Children's Oncology Group
Eisai Inc.
Children's Oncology Group
Eastern Cooperative Oncology Group
Istituto Ortopedico Rizzoli
National Cancer Institute (NCI)
Institut Curie
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Assiut University
St. Jude Children's Research Hospital
Children's Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Mayo Clinic
National Cancer Institute (NCI)
Children's Oncology Group
City of Hope Medical Center
Dana-Farber Cancer Institute
Columbia University
Children's Oncology Group
Children's Oncology Group
University of Iowa
Teva Branded Pharmaceutical Products R&D, Inc.
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Rutgers, The State University of New Jersey
City of Hope Medical Center
Children's Oncology Group
National Cancer Institute (NCI)